Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Celularity Inc (CELU)

$0.75 -1.32% NASDAQ: CELU · 15-min delayed
  • FLORHAM PARK, New Jersey
  • Public · NASDAQ: CELU
  • 115 employees
$25.2MMarket cap
$26.6MRevenue · FY2025
-$91.7MNet income
115Employees
CELUNASDAQ
2021IPO

About Celularity Inc

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$26.6M
Net income
-$91.7M
Total assets
$107.3M
Market cap
$25.2M
Gross margin
72.4%
Operating margin
-70.7%
Net margin
-106.8%

Source: SEC EDGAR · updated Jun 8, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2024

Financial statements

Income statement

Revenue
$54.2M
Cost of revenue
$15.0M
Gross profit
$39.2M
Operating expenses
$77.6M
Operating income
-$38.4M
Net income
-$57.9M
EPS (basic)
$-2.64
EPS (diluted)
$-2.64

Balance sheet

Total assets
$132.7M
Current assets
$20.6M
Total liabilities
$123.8M
Current liabilities
$53.7M
Shareholders’ equity
$8.8M

Cash flow

Operating cash flow
-$6.4M
Investing cash flow
$514.0K
Financing cash flow
$6.7M
Net cash flow
$814.0K

Statements via Polygon.io (SEC filings)

NASDAQ: CELU
$0.75 -1.32%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.60 $4.15

52-week range

Market cap
$25.2M
EPS (diluted)
$-2.64
Shares outstanding
33.7M
Open
Day range
Prev close
Volume
IPO date
Jul 19, 2021

Celularity Inc (CELU) Stock Price

  • Reported a net loss of $91.7M in FY2025.
  • Revenue grew 154% from FY2021 to FY2024.
  • Gross margin of 72.4%, net margin -106.8%.
  • Trading 82% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Celularity Inc.

Write a review
Newsroom

News about Celularity Inc

News & sentiment via Polygon.io

FAQ

Celularity Inc: frequently asked questions

Is Celularity Inc an American company?

Celularity Inc is a US-based company headquartered in Florham Park, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Celularity Inc headquartered?

Celularity Inc is headquartered in Florham Park, New Jersey, United States.

Is Celularity Inc publicly traded?

Yes — Celularity Inc is a publicly traded company. Its stock trades under the ticker symbol CELU on the NASDAQ.

What does Celularity Inc do?

Celularity Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →